The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients
Abstract
Chronic cold agglutinin disease (CAD) is an acquired autoimmune hemolytic anemia. Previous therapeutic modalities, including alkylating cytostatics, interferon and prednisolone, have been disappointing. However, several case reports and small-scaled studies have demonstrated promising results after treatment with rituximab. We performed a phase II multicentre trial to investigate the effect of rituximab in CAD, including 20 patients studied from October 2002 until April 2003. Thirteen patients had idiopathic CAD and seven patients had CAD associated with a malignant B-cell lymphoproliferative disease. Rituximab was given in doses of 375 mg/m(2) at days 1, 8, 15 and 22. Sixteen patients were followed up for at least 48 weeks. Four patients were excluded after 8, 16, 23 and 28 weeks for reasons unrelated to CAD. Nine patients (45%) responded to the treatment, one with complete response (CR), and eight with partial response. Eight patients relapsed, one patient was still in remission at the end of follow-up. There were no serious rituximab-related side-effects. Our study confirms previous findings of a favourable effect of rituximab in patients with CAD. However, few patients will obtain CR and, in most patients, the effect will be transient.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
Teeling, J. L. (2004) · Blood · doi:10.1182/blood-2004-01-0039 · Cited by 630
Cited by
Jäger, U., Barcellini, W., Broome, C. M., Gertz, M. A., Hill, A., Hill, Q. A., Jilma, B., Kuter, D. J., Michel, M., Montillo, M., et al. (2020) · Blood Reviews · doi:10.1016/j.blre.2019.100648 · Cited by 565
Merlini, G., & Stone, M. J. (2006) · Blood · doi:10.1182/blood-2006-03-001164 · Cited by 463
Barcellini, W., Fattizzo, B., Zaninoni, A., Radice, T., Nichele, I., Di Bona, E., Lunghi, M., Tassinari, C., Alfinito, F., Ferrari, A., et al. (2014) · Blood · doi:10.1182/blood-2014-06-583021 · Cited by 382
Swiecicki, P. L., Hegerova, L. T., & Gertz, M. A. (2013) · Blood · doi:10.1182/blood-2013-02-474437 · Cited by 324
A review of the current use of rituximab in autoimmune diseases
Gürcan, H. M., Keskin, D. B., Stern, J. N. H., Nitzberg, M. A., Shekhani, H., & Ahmed, A. R. (2009) · International Immunopharmacology · doi:10.1016/j.intimp.2008.10.004 · Cited by 314
Metadata
- Authors
- Schöllkopf, C., Kjeldsen, L., Bjerrum, O. W., Mourits-Andersen, H. T., Nielsen, J. L., Christensen, B. E., Jensen, B. A., Pedersen, B. B., Taaning, E. B., Klausen, T. W., & Birgens, H.
- Venue
- Leukemia & Lymphoma
- Publisher
- Informa UK Limited
- Published
- 2006-01
- Volume
- 47
- Issue
- 2
- Pages
- 253-260
- ISSN
- 1026-8022 (ISSN-L)
- 1042-8194
- 1029-2403
- OpenAlex
- W1975338840
- Cited by
- 175
- References
- 2
- FWCI
- 4.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. https://app.cochat.ai/papers/10.1080/10428190500286481
- The paper
- Schöllkopf, C., Kjeldsen, L., Bjerrum, O. W., Mourits-Andersen, H. T., Nielsen, J. L., Christensen, B. E., Jensen, B. A., Pedersen, B. B., Taaning, E. B., Klausen, T. W., & Birgens, H. (2006). Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. Leukemia & Lymphoma. https://doi.org/10.1080/10428190500286481
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.